This was originally posted by Cision PR Newswire SALT LAKE CITY, July 9, 2020 /PRNewswire/ -- HealthTree®, the first online portal...
Research
FDA Places MELANI-01 Study for Multiple Myeloma on Hold After Safety Report Submission
This article was originally published by Cancer Network Cellectis recently announced the FDA placed its MELANI-01 trial treating multiple myeloma on...
Patients with Multiple Myeloma and CHIP Face Worse Outcomes Following ASCT
However, when followed by immunomodulatory drugs, researchers found that autologous stem cell transplant can be safely used in this patient...
Once-weekly selinexor regimen extends PFS in pretreated multiple myeloma
This article was originally published by Healio Once-weekly selinexor, bortezomib and dexamethasone improved outcomes compared with twice-weekly...
CAR T-Cell Therapies Show Promise for Multiple Myeloma, but Hurdles Remain
This article was originally published by AJMC There are promising signs that chimeric antigen receptor (CAR) T-cell therapies might lead to...
Dr. Kumar on Stem Cell Mobilization in Multiple Myeloma
This article originally published by OncLive Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses stem cell mobilization multiple...
Impact of age, sex, ethnicity, socio-economic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand
The impact of age, ethnicity and socio-economic deprivation in the era of novel anti-myeloma agents is unclear. Using linked national data from New...